A new study demonstrates that minimally invasive blood collection devices could increase the participation of people experiencing homelessness (PEH) in public health studies and clinical research.
The U.S. Food and Drug Administration (FDA) has long sparked controversy with its proposals to regulate laboratory developed tests (LDTs) as medical devices.
Breaking research demonstrates that clinical labs should account for the self-reported race of pregnant individuals when screening for spina bifida and other open neural tube defects. This finding, which was presented today in the Association for Diagnostics & Laboratory Medicine’s (formerly AACC’s) Clinical Chemistry journal, could improve prenatal care for pregnant Black individuals.
To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven’s untimely death. However, a new letter to the editor in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) journal Clinical Chemistry rules out one popular theory, showing that the composer was exposed to lead levels that were high — but not high enough to kill him.
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued a new guidance document that provides expert recommendations on fundamental areas of clinical testing for respiratory viral infections. As respiratory virus testing continues to evolve rapidly in the wake of the COVID-19 pandemic, this guidance aims to ensure that patients benefit fully from emerging technologies in this field.
We at the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) strongly disagree with the Food and Drug Administration’s (FDA’s) decision to issue a final rule placing laboratory developed tests under duplicative FDA authority, in addition to these tests’ current regulation under the Centers for Medicare & Medicaid Services (CMS).
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is proud to announce the recipients of the 2024 ADLM and Academy of Diagnostics & Laboratory Medicine Awards. Through this annual awards program, ADLM and its Academy recognize individuals around the world for outstanding research and service in the field of laboratory medicine and highlight the vital contributions made by all lab professionals to patient care.
Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released the results of a survey the organization conducted to determine how the Food and Drug Administration’s (FDA’s) proposed laboratory developed tests rule would impact patient care.
“Today, we at the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) provided testimony to Congress regarding the impact of the Food and Drug Administration’s (FDA’s) proposed rule to impose FDA oversight on laboratory developed tests in addition to Centers for Medicare & Medicaid Services (CMS) oversight. While we share FDA’s goal of ensuring that laboratory developed tests are safe and effective, we have serious concerns about the agency’s proposal. If finalized, this rule would create a burdensome dual regulatory structure that would limit patient access to many life-saving tests.
A new tuberculosis (TB) test disclosed in the Association for Diagnostics & Laboratory Medicine’s (formerly AACC’s) Clinical Chemistry journal would allow testing for TB treatment monitoring to occur outside of a biosafety level 3 (BSL-3) laboratory.
“We at the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) were surprised to see a statement from Drs. Jeff Shuren and Dora Hughes from the Centers for Medicare & Medicaid Services (CMS) in support of the U.S. Food & Drug Administration’s (FDA’s) proposed rule to duplicate the regulation of laboratory developed tests by placing these tests under FDA authority, in addition to their current regulation under CMS.
A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs).
The Association for Diagnostics & Laboratory Medicine’s (formerly AACC’s) Clinical Chemistry journal released a special issue today titled “Cancer: Biology and Diagnostics,” which presents a wide range of discoveries with the potential to improve cancer diagnosis and treatment.
Molecular diagnostics is a powerful branch of laboratory medicine that examines the fundamental genetic and biochemical components of life to provide invaluable insights into health and disease.
A special report published today in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.
A report published today in the Association for Diagnostics & Laboratory Medicine’s (formerly AACC’s) The Journal of Applied Laboratory Medicine describes the strategies used by the National Basketball Association (NBA) to limit COVID-19 exposure among the individuals who participated in the 2019–2020 season. The success of the NBA’s approach demonstrates that strict adherence to certain protocols can be highly effective in preventing disease outbreaks in a self-contained environment and serves as a model for future pandemic management.
Join the Association for Diagnostics & Laboratory Medicine (formerly AACC) and leading experts in laboratory medicine and pediatric health for a discussion about what needs to be done to improve pediatric reference intervals and why this is critical to ensuring that children get effective care.
The Association for Diagnostics & Laboratory Medicine (ADLM) is pleased to announce that Maritel Dasco assumed the position of chief financial officer (CFO) for the association on September 25.
We at the Association for Diagnostics & Laboratory Medicine were disappointed to see the U.S. Food & Drug Administration’s (FDA’s) attempt to circumvent Congress with its new proposed rule to duplicate the regulation of laboratory developed tests by placing these tests under FDA authority, in addition to their current regulation under the Centers for Medicare and Medicaid Services.
A new survey from the Association for Diagnostics & Laboratory Medicine (formerly AACC) found that clinical labs’ robust, rapid response to the COVID-19 pandemic helped to contain the virus and save lives. However, the challenges labs faced with insufficient supplies and staffing shortages have only intensified since 2020. The percentage of laboratory professionals reporting staffing issues rose steadily from 35.4% in May 2020 to 87.5% in January 2022—raising questions about whether labs would have the necessary resources to respond to a similar public health emergency today.
The Association for Diagnostics and Laboratory Medicine (ADLM), formerly AACC, welcomed thousands of laboratory experts to the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo from July 23-27. At this year’s special meeting celebrating ADLM’s 75th anniversary, the organization officially rolled out a new name that reflects the association’s role as advocate and champion for a larger community specializing in diagnostics and laboratory medicine, as well as its global reach.
Zymo Research Corp, a leading provider of life science technologies, has partnered with Opentrons Labworks, Inc., a leader in lab automation, to revolutionize cell-free DNA isolation and analysis.
Two studies featured today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo highlight advances that could boost the accuracy of marijuana tests and provide vital information for addressing the opioid epidemic.
Shenzhen Superbio Technology Co., LTD. (Superbio) has received clearance from the US Food and Drug Administration (FDA) on the first ever point-of-care instrument intended for qualitative detection of fentanyl in human urine and has fully released authorization to Bioeasy USA, Inc.(Bioeasy) of this product in the United States of America.
PBD Biotech developers of Actiphage TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit. The company is exhibiting in the AACC Clinical Lab Expo on booth #4578.
A new artificial intelligence model can predict people’s risk of multiple sclerosis years before diagnosis, potentially enabling quicker treatment, according to research revealed today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
Today, at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo, scientists will present new data about rates of co-infections with SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) in the United States.
Taiwanese IVD (In-Vitro Diagnostic) manufacturer General Biologicals Corporation (GBC) today unveiled two CellBio™ circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, being held July 23-27 in Anaheim, California.
As a leader in pre-analytic innovation, SARSTEDT provides 360 solutions for improving specimen quality, reducing turnaround time, and automating labs of all sizes with customizable modular systems.
New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a name change to the Association for Diagnostics & Laboratory Medicine.
At the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory experts will present cutting-edge research and technology that is shaping the future of clinical testing and patient care.
During the AACC - Annual Scientific Meeting & Clinical Lab Expo, held in Anaheim, California (USA) from July 23rd to 27th, the Brazilian health tech company Hilab, specializing in clinical analysis tests, participated in the congress alongside ABIMO - Brazilian Association of Medical Devices Industry.
During the AACC - Annual Scientific Meeting & Clinical Lab Expo, held in Anaheim, California (USA) from July 23rd to 27th, the Brazilian health tech company Hilab, specializing in clinical analysis tests, participated in the congress alongside ABIMO - Brazilian Association of Medical Devices Industry.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the American Association for Clinical Chemistry (AACC) annual meeting and expo held July 23-27, 2023 in Anaheim, CA.
Today, AACC—in collaboration with the American Diabetes Association (ADA)—released evidence-based guidelines to help diagnose and manage patients with diabetes using the latest laboratory-analysis tools. The guidelines replace previous versions published in 2002 and 2011. The new document features extensive updates on continuous glucose monitoring and more precise recommendations for measuring glucose and hemoglobin A1c, a marker of average blood glucose. Written by a cross-disciplinary team of medical experts, the guidelines provide specific, actionable advice that will enhance collaboration among healthcare professionals and improve care for millions of people.
Prevencio, Inc. today announces the culminative presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART® blood tests are highly accurate in a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the journal Clinical Chemistry received an impact factor of 9.3 —the second highest in the journal’s history—and the Journal of Applied Laboratory Medicine (JALM) received its first impact factor, of 2.0, according to the newly released 2022 Clarivate Journal Citation Reports.
Today, AACC—in collaboration with the National Kidney Foundation (NKF)—released guidance to reduce racial and gender disparities in the care of patients with chronic kidney disease (CKD). The document gives members of the healthcare team actionable, evidence-based tools to improve equity in kidney health, including recommendations for using an updated algorithm that does not disproportionately affect any one group of individuals.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Anthony A. Killeen, MB, BCh, PhD, MSc, has been elected to serve on the AACC board of directors as president-elect starting in August 2023. Following this, he will serve successive terms as the association’s president from August 2024-July 2025 and as past president from August 2025-July 2026. In addition, the AACC membership elected a new secretary and two new directors to the association’s board. They will take office in August 2023 along with the incoming president of AACC Academy and the incoming chair of the AACC Clinical Laboratory Scientists Council, both of whom will also serve on the board.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2023 AACC and AACC Academy Awards. Through this annual awards program, AACC strives to support laboratory medicine professionals in all stages of their careers and to build awareness of the essential role that clinical laboratory testing plays in improving patient health.
AACC has issued expert guidance on clinical testing for procalcitonin, a blood marker that helps detect serious bacterial infections and sepsis. By giving clinicians and laboratory professionals much-needed clarity on how to best use procalcitonin tests, the new guidelines could improve the treatment of critically ill patients and those with certain lower respiratory infections.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that MaryAnne Elma has assumed the position of chief science and policy officer for the association, effective today.
A first-of-its-kind study has established pediatric reference intervals for two common tests for cardiovascular disease. Published in AACC’s The Journal of Applied Laboratory Medicine, these findings are crucial to advancing diagnosis and treatment of heart conditions in children.
Scientists have developed a test that could greatly improve quality of life for infants with homocystinuria (HCU)—a congenital disease that, if not treated early, causes serious complications. Research demonstrating the efficacy of this test was published today in AACC’s Clinical Chemistry journal.